Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gut-Brain chat may explain why we overeat

NCT ID NCT05646901

Knowledge-focused Sponsor: Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how gut bacteria and the brain communicate in people with obesity, and whether this affects eating control. Researchers will study 116 adults aged 30-65, using brain scans, blood tests, and questionnaires. No treatment is given; the goal is to understand the connection between gut microbes, brain activity, and eating behavior.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could reveal how gut bacteria influence eating habits and brain function, pointing toward new ways to manage obesity.
What could go wrong
This is an observational study, not a treatment trial. It may not find clear links, and results may not lead to direct therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 116 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2022

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with obesity, without known type 2 diabetes, previously scheduled at the Service of Endocrinology, Diabetes, and Nutrition (UDEN) of the Hospital "Dr. Josep Trueta" of Girona (Spain) will be recruited and studied. Subjects without obesity will also be recruited through a public announcement.

Ages

30 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Men and women aged 30-65 years. 2. Informed consent for participation in the study. Exclusion Criteria: 1. Serious systemic disease unrelated to obesity such as cancer, severe kidney, or liver disease, known as type 1 or type 2 diabetes. 2. Systemic diseases with intrinsic inflammatory activity such as rheumatoid arthritis, Crohn's disease, asthma, chronic infection (e.g., HIV, active tuberculosis), or any type of infectious disease. 3. Pregnancy and lactation. 4. Patients with severe disorders of eating behavior. 5. Persons whose liberty is under the legal or administrative requirement. 6. Clinical symptoms and signs of infection in the previous month. 7. Antibiotic, antifungal or antiviral treatment in the previous 3 months. 8. Anti-inflammatory chronic treatment with steroidal and/or non-steroidal anti-inflammatory drugs. 9. Major psychiatric antecedents. 10. Excessive alcohol intake, either acute or chronic (alcohol intake greater than 40 g a day (women) or 80 g/day (men)) or drug abuse. 11. Serum liver enzyme (AST, ALT) activity over twice the upper limit of normal. 12. History of disturbances in iron balance (e.g., genetic hemochromatosis, hemosiderosis from any cause, atransferrinemia, paroxysmal nocturnal hemoglobinuria). 13. Creatinine greater than 1.2 and glomerular filtration rate less than 40. 14. Immunosuppressants treatment. 15. Chronic constipation (depositional habit ≥ 7 days) 16. Kidney failure, history of a kidney transplant, or current treatment with dialysis. 17. Treatment with a slimming product during the previous two months. 18. Class III or IV heart failure (according to the New York Heart Association), medical records of ischemic cardiovascular disease. 19. Current treatment for malignant neoplasm.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Institut d'Investigació Biomèdica de Girona (IDIBGI)

    RECRUITING

    Girona, Girona, 17007, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.